Ajanta Pharma USA Inc Fenofibrate Capsules, USP 200 mg recall: CGMP Deviations
CGMP Deviations
The hazard: Labelling or manufacturing-practice failure
This recall is about what the packaging says rather than what is in it — which still matters, because the label is how a dose gets chosen.
What the notice says: CGMP Deviations
Why it matters: The label, the strength printed on it, the barcode or the manufacturing records do not meet federal requirements. The practical danger is someone taking the wrong drug or the wrong dose while believing they have the right one.
Symptoms and when to call a doctor
If you may have taken a product that turned out to be a different drug or strength from the one on the label, call your prescriber, and call Poison Control on 1-800-222-1222 if you feel unwell. Describe what the pack said and what you actually took.
This page is general information, not medical advice. If you feel unwell, a clinician who can see you is the only person able to judge your case.
Recall details
- Recall number
- D-0611-2026
- Published
- July 1, 2026
- Risk level
- Class II
- Status
- Ongoing
- Issued by
- U.S. Food and Drug Administration
- Brand
- Ajanta Pharma USA Inc
- Product type
- Prescription & OTC drugs
- Units affected
- 3648 bottles
- Distribution
- Nationwide
- Made in
- United States
- Lot / code info
- Lot # PA02216; Exp. 12/2029
Products covered by this recall
Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules, Manufactured by: Ajanta Pharma Limited, India, Marketed by: Ajanta Pharma USA Inc. Bridgewater, NJ 08807, NDC 27241-120-04.
Check your product
The notice names 5 codes you can read straight off the package. Type the one printed on yours and the list below narrows to it.
Lot or batch code
Usually ink-stamped near the seam, the cap or the bottom of the pack.
- PA02216
Best-by / use-by date
Printed beside the lot code, not on the price sticker.
- 12
- 2029 — 3648 bottles
NDC number
On the carton and again on the bottle or blister label.
- 27241-120-04
Package size
Match the net weight or the piece count on the front of the pack.
- 200 mg
Codes are lifted verbatim from the FDA — Drug enforcement notice. A code that is missing here may still be covered — the official notice is the complete list.
What to do about Labelling
Ajanta Pharma USA Inc — This recall is about what the packaging says rather than what is in it — which still matters, because the label is how a dose gets chosen.
- Compare the lot number and strength on your pack with the codes above and with what your prescription actually says.
- Keep taking the medicine as prescribed unless the notice or your prescriber says otherwise.
- Return the affected pack to the pharmacy for a replacement from a good lot.
- Report a mismatch to FDA MedWatch, especially if it reached you rather than being caught at the counter.
Refunds and replacements
With medicines, a replacement supply matters more than cash, and that is what pharmacies are set up to provide.
- Ask the dispensing pharmacy for a like-for-like replacement from an unaffected lot. This is the fastest route and usually costs nothing.
- For a mail-order or online pharmacy, use the recall line listed on this page rather than the general support queue.
- If the recall voided a fill you had already paid for, your insurer will normally authorise a replacement ahead of schedule. Quote the recall number.
- If you paid out of pocket, ask for a refund of the co-pay or purchase price and keep the receipt the pharmacy issues.
Company contact: Ajanta Pharma USA Inc — 400 Crossing Blvd Ste 102, Bridgewater, NJ, 08807-2863
The official notice
This page summarises a notice published by U.S. Food and Drug Administration. The agency notice is the authoritative version — read it before you act, and treat it as the final word if anything here looks different.
Open the FDA — Drug enforcement record U.S. Food and Drug Administration recalls
Questions people ask about this recall
Why was Ajanta Pharma USA Inc prescription & otc drugs recalled?
CGMP Deviations CGMP Deviations
How do I know if I have the recalled product?
Match the codes printed on your package against the notice: lot code PA02216; best-by date 12 or 2029 — 3648 bottles. If the code on your package is not on that list, your unit is outside the recall.
What should I do with it right now?
Compare the lot number and strength on your pack with the codes above and with what your prescription actually says.
Can I get my money back?
Ask the dispensing pharmacy for a like-for-like replacement from an unaffected lot. This is the fastest route and usually costs nothing.
Where was the recalled product sold?
It was distributed nationwide.
Related recalls
-
Class II · 18 days ago
Ajanta Pharma USA Inc Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle recall: Failed Dissolution Specifications: below specification
Failed Dissolution Specifications: below specification
-
Class III · last month
Ajanta Pharma USA Inc Fluphenazine Hydrochloride Tablets, USP, 1mg, 100-count bottles recall: Failed impurities/degradation specifications: (OOS) for Organic Impurities
Failed impurities/degradation specifications: (OOS) for Organic Impurities by HPLC (Impurity-A) during testing at the 18 months long term stability…
-
Class II · 4 months ago
Ajanta Pharma USA Inc Aripiprazole Tablets USP recall: Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled
Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
-
Class II · 6 months ago
Ajanta Pharma Ltd. Duloxetine Delayed-Release Capsules, 30 mg recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term…
-
Class II · 6 months ago
Ajanta Pharma Ltd. Duloxetine Delayed-Release Capsules, 20 mg recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term…
-
Class II · 6 months ago
Ajanta Pharma Ltd. Duloxetine Delayed-Release Capsules, 60 mg recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term…